INTRODUCTION AND OBJECTIVES: Multiparametric magnetic resonance imaging (mpMRI) fusion biopsy has been demonstrated to detect clinically significant prorstate cancer (CSPCa) as compared to standard transrectal ultrasound (TRUS) guided biopsy but an optimal PSA threshold for its use is unclear. We evaluated the clinically significant cancer detection rate of MRI fusion biopsy stratified across PSA cutoffs.
METHODS: We reviewed 670 men undergoing MRI-fusion and standard TRUS guided prostate biopsy from January 2016 to June 2018. Patients were divided into 3 groups by PSA: <4, 4-10 and >10 ng/mL. The greatest grade form either or standard biopsy (n[333) was compared, clinically-significant (CSPCa) defined as Gleason-score 3þ4 or greater.
RESULTS: A total of 348/670 (52%) men were diagnosed with PCa by either biopsy method. The rate of GS 7 or greater PCa was 134/ 337 (38.9%) in MRI-fusion biopsy and 124/333 (37.2%) in standard biopsy (p[0.38) . By PSA groups, significantly more patients with PSA 4-10 ng/mL had CSPCa found by MRI-fusion vs standard biopsy (63/196 (32.1%) METHODS: We retrospectively analyzed all patients who underwent prebiopsy prostate mpMRI for suspicion of prostate cancer from January 2016 to June 2018. Negative mpMRI was defined as Prostate Imaging Reporting and Data System version 2 (PIRADSv2) <3. CSPCa defined as a Gleason score ! 3þ4. We analyzed the final pathologic finding in men with negative mpMRI but positive findings of prostate adenocarcinoma after prostatectomy. RESULTS: Overall, 337 patients underwent MRI-TRUS fusion biopsy between January 2016 and June 2018. 53% (178/337) patients had negative mpMRI. Among them, 24% (42/178) patients had prostate cancer (GS6: 50%, CSPCa: 50%) (figure 1). On these patients, 19 patients underwent prostatectomy (RALP in 17, RRP in 2). Their mean age was 65.6 (58e77) years, median PSA was 6.8 (4e12.4) ng/mL, median PSA density was 0.18 (0.07-0.44) ng/mL2. On final surgical pathology, 84% (16/19) patients had CSPCa (Gleason 7 (3þ4) : 11, Gleason 7 (4þ3) : 3 and Gleason 8 (4þ4) : 2). 31% (6/19) patients upgraded on surgical pathology from biopsy pathology, and 31% (6/19) patients had extra prostatic extension including 1 seminal vesicle extension.
CONCLUSIONS: In negative mpMRI, 24% (42/178) patient had prostate cancer. Among them, 50% (21/42) had CSPCa. Thus, our study shows the importance of a systemic biopsy despite negative mpMRI findings in patients with suspicion for prostate cancer.
